Skip to main content
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ABOS ISIN · US00509G2093 US Manufacturing
Open in API
Filings indexed 309 across all filing types
Latest filing 2026-06-03 Declaration of Voting R…
Country US United States of America
Listing US ABOS

About Acumen Pharmaceuticals, Inc.

https://acumenpharm.com/

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer's disease. The company's approach is based on research into toxic soluble amyloid beta oligomers (AβOs), which are considered a primary driver of neurodegeneration associated with the disease. Its lead product candidate, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target these toxic AβOs. Sabirnetug is being developed as a potential disease-modifying treatment for early Alzheimer's, with the goal of providing therapeutic benefits with an improved safety profile.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed under Item 5.07 (“Submission of Matters to a Vote of Security Holders”) reporting the detailed voting results from the company’s 2026 annual meeting. It solely provides vote tallies for proposals, matching the disclosure of shareholder voting results. This fits the “Declaration of Voting Results & Voting Rights Announcements” category (Code: DVA).
2026-06-03 English
10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
Report Publication Announcement Classification · 80% confidence The document is a Form 8-K filing that does not itself contain financial data but instead furnishes an earnings press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2). It is under 5,000 characters and simply announces the publication of these reports rather than presenting substantive financial statements. According to the “menu vs. meal” rule, this is an announcement that reports are attached and thus fits our Report Publication Announcement category.
2026-05-12 English
424B3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933, related to the resale of shares by selling stockholders from a private placement. It includes detailed information about the offering, selling stockholders, plan of distribution, risk factors, company overview, and other disclosures typical of a prospectus. It is not an annual report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report. The document is a registration prospectus related to capital raising and share resale, which fits the category of Capital/Financing Update (CAP).
2026-04-01 English
S-8 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a detailed calculation of filing fees related to a securities registration statement, specifically for newly registered securities under an S-8 form. It includes tables showing the number of shares registered, fee calculations, and notes about the equity incentive plans and employee stock purchase plans. The presence of the S-8 form and the focus on registration fees for securities issuance indicates this is a capital raising or share registration filing. There is no financial performance data, management discussion, or audit information. The document is not an announcement of a report but a regulatory filing related to securities registration. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-26 English
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation dated March 2026, discussing Acumen Pharmaceuticals' drug development pipeline, clinical trial phases, biomarker data, leadership team, financial status, and upcoming milestones. It includes forward-looking statements, clinical trial results, and strategic plans. The content is typical of an investor presentation aimed at providing comprehensive information about the company's business, financial position, and future outlook to investors. There is no indication that this is an official regulatory filing like an Annual Report (10-K) or an Earnings Release (ER). It is not a transcript of a call, nor a voting result announcement, nor a legal or audit report. The document is too long and detailed to be a simple report publication announcement or a regulatory filing. Therefore, the best fit classification is Investor Presentation (IP).
2026-03-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.